Concepedia

L.S. Wyrwicz

LW

Statistics

Publications

2

Citations

76

H-Index

2

Active since

2023

Affiliations

The Maria Sklodowska-Curie National Research Institute of Oncology(Current)

L.S. Wyrwicz is an author at The Maria Sklodowska-Curie National Research Institute of Oncology specializing in neoplasia, oncology, and chemotherapy.

Publications per year

2023–2025

2

Publications

2

VP1-2023: Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study

Sun Young Rha, L.S. Wyrwicz, P.E. Yanez Weber et al. · Annals of Oncology · 2023 · 66 citations · Full text

, , +13

LBA81 Final overall survival (OS) and the association of pathological outcomes with event-free survival (EFS) in MATTERHORN: A randomised, phase III study of durvalumab (D) plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric / gastroesophageal junction (G / GEJ) adenocarcinoma

J. Tabernero, S-E. Al-Batran, Zev A. Wainberg et al. · Annals of Oncology · 2025 · 10 citations

, , +9

1–2 of 2